Key statistics dashboard for Clene Inc. (CLNN). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS).
Stock Data
| Price | $3.86 |
| Market Cap | $49M |
| Beta | 0.62 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.13 |
| Price / Book | -2.01 |
| P/S | 260.76 |
| P/FCF | -3.22 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | -110.15% |
| EBIT Margin | -14850.25% |
| EBITDA Margin | -14122.84% |
| Operating Margin | -10304.57% |
| Net Margin | -20059.90% |
Financial Health
| Current Ratio | 3.07 |
| Quick Ratio | 3.07 |
| Cash Ratio | 1.99 |
| Debt / Equity | -0.90 |
| Debt / Assets | 96.97% |
| Interest Coverage | -7.05 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -27.14 |
Per-Share Data
| Revenue per share | 0.02 |
| Book Value per share | -2.00 |
| Cash per share | 0.78 |
| FCF per share | -1.29 |
| Tangible Book Value per share | -2.00 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 7 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 8 |
| Avg rating (1-5) | 0.88 |
Related companies: CNTB · CNTX · COYA · MGNX · ORMP · OVID · PLRX
Explore sector: Healthcare · Biotechnology
More sections of CLNN: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks